RecruitingPhase 1

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

United States12 participantsStarted 2026-03-23

Plain-language summary

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate: 1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation. 2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation 3. To study impact of GGC on gut health on the PD patients.

Who can participate

Age range50 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed Parkinson's Disease diagnosis. * Montreal Cognitive Assessment (MoCA) greater than or equal to 26. * Age (50 to 80 years of age). * Ability to read and write in English. Exclusion Criteria: * Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments in the eyes, skin, or body. * Subjects with claustrophobia. * Patients with a clinical diagnosis of Parkinson's disease dementia or dementia with Lewy bodies. * Subjects with a history of cancer. * Subjects with active psychosis or delirium. * Subjects with chronic kidney (creatinine \> 1.5mg/dL) or liver disease (AST ≥ 1.5 ULN; ALT ≥ 1.5 ULN) within 30 days prior to enrolment. * Subjects on antioxidant therapy (ashwagandha, gingko biloba or N-acetylcysteine) or illicit drug abuse/dependence (cocaine, heroin, marijuana, or fentanyl). * Subjects with previous traumatic head injury.

What they're measuring

Changes in brain glutathione levels (mM) in people with Parkinson's Disease using Magnetic Resonance Spectroscopy compared to post-supplementation with GGC.

Timeframe: 12 months

Changes in brain iron levels (ppb) in people with Parkinson's Disease using Magnetic Resonance Imaging between pre and post GGC supplementation.

Timeframe: 12 months

Changes in baseline blood iron levels(ng/μl) in people with Parkinson's Disease

Timeframe: 12 months

Changes in baseline blood glutathione levels (µmol/l) in people with Parkinson's Disease compared to post-supplementation with GGC

Timeframe: 12 months

Trial details

NCT IDNCT07064005

SponsorPravat Mandal

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2027-09

Contact for this trial

Pravat K MANDAL, PHD

4126999561 mandalpk@pitt.edu

View on ClinicalTrials.gov More Parkinsons Disease (PD) trials

Plain-language summary

Who can participate

Age range50 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Changes in brain glutathione levels (mM) in people with Parkinson's Disease using Magnetic Resonance Spectroscopy compared to post-supplementation with GGC.

Timeframe: 12 months

Changes in brain iron levels (ppb) in people with Parkinson's Disease using Magnetic Resonance Imaging between pre and post GGC supplementation.

Timeframe: 12 months

Changes in baseline blood iron levels(ng/μl) in people with Parkinson's Disease

Timeframe: 12 months

Changes in baseline blood glutathione levels (µmol/l) in people with Parkinson's Disease compared to post-supplementation with GGC

Timeframe: 12 months